Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia

L. G. Melstrom, K. A. Melstrom, X. Z. Ding, Thomas E. Adrian

Research output: Contribution to journalReview articlepeer-review

63 Citations (Scopus)

Abstract

Severe or chronic disease can lead to cachexia which involves weight loss and muscle wasting. Cancer cachexia contributes significantly to disease morbidity and mortality. Multiple studies have shown that the metabolic changes that occur with cancer cachexia are unique compared to that of starvation. Specifically, cancer patients seem to lose a larger proportion of skeletal muscle mass. There are three pathways that contribute to muscle protein degradation: the lysosomal system, cytosolic proteases and the ubiquitin (Ub)-proteasome pathway. The Ub-proteasome pathway seems to account for the majority of skeletal muscle degradation in cancer cachexia and is stimulated by several cytokines including tumor necrosis factor-α, interleukin-1β, interleukin-6, interferon-γ and proteolysis-inducing factor. Cachexia is particularly severe in pancreatic cancer and contributes significantly to the quality of life and mortality of these patients. Several factors contribute to weight loss in these patients, including alimentary obstruction, pain, depression, side effects of therapy and a high catabolic state. Although no single agent has proven to halt cachexia in these patients there has been some progress in the areas of nutrition with supplementation and pharmacological agents such as megesterol acetate, steroids and experimental trials targeting cytokines that stimulate the Ub-proteasome pathway.

Original languageEnglish
Pages (from-to)805-814
Number of pages10
JournalHistology and Histopathology
Volume22
Issue number7-9
Publication statusPublished - Jul 2007
Externally publishedYes

Keywords

  • Cancer cachexia
  • Skeletal muscle degradation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Fingerprint

Dive into the research topics of 'Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia'. Together they form a unique fingerprint.

Cite this